[go: up one dir, main page]

CN104098499B - The preparation method of 5-benzyloxy-2-(4-benzyloxy phenyl)-3-Methyl-1H-indole - Google Patents

The preparation method of 5-benzyloxy-2-(4-benzyloxy phenyl)-3-Methyl-1H-indole Download PDF

Info

Publication number
CN104098499B
CN104098499B CN201310120074.4A CN201310120074A CN104098499B CN 104098499 B CN104098499 B CN 104098499B CN 201310120074 A CN201310120074 A CN 201310120074A CN 104098499 B CN104098499 B CN 104098499B
Authority
CN
China
Prior art keywords
acid
preparation
reaction
compound
benzyloxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201310120074.4A
Other languages
Chinese (zh)
Other versions
CN104098499A (en
Inventor
陈姗
袁哲东
刘相奎
孔锐
顾红梅
王祥建
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Institute of Pharmaceutical Industry
Chia Tai Tianqing Pharmaceutical Group Co Ltd
China State Institute of Pharmaceutical Industry
Original Assignee
Shanghai Institute of Pharmaceutical Industry
Chia Tai Tianqing Pharmaceutical Group Co Ltd
China State Institute of Pharmaceutical Industry
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Institute of Pharmaceutical Industry, Chia Tai Tianqing Pharmaceutical Group Co Ltd, China State Institute of Pharmaceutical Industry filed Critical Shanghai Institute of Pharmaceutical Industry
Priority to CN201310120074.4A priority Critical patent/CN104098499B/en
Publication of CN104098499A publication Critical patent/CN104098499A/en
Application granted granted Critical
Publication of CN104098499B publication Critical patent/CN104098499B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/10Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12Radicals substituted by oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Indole Compounds (AREA)

Abstract

The invention discloses the preparation method of 5-benzyloxy-2-(4-benzyloxy phenyl)-3-Methyl-1H-indole. This preparation method comprises the following steps: that (1) is in alcohols solvent, under the effect of alkali, Compound I I and compound III is carried out to condensation reaction; (2) reactant liquor of step (1) is mixed with Bronsted acid, carries out Bischler-Mohlau indoles ring closure reaction. Synthetic route of the present invention is compared with original technology, first step condensation reaction is merged into " one pot " with second step Bischler-Mohlau indoles ring closure reaction and react, easy and simple to handle; Product I directly separates out from reaction dissolvent, has greatly simplified post-reaction treatment process, and purity is high, and reaction yield is high, is suitable for amplifying producing.

Description

5-苄氧基-2-(4-苄氧基苯基)-3-甲基-1H-吲哚的制备方法The preparation method of 5-benzyloxy-2-(4-benzyloxyphenyl)-3-methyl-1H-indole

技术领域technical field

本发明涉及5-苄氧基-2-(4-苄氧基苯基)-3-甲基-1H-吲哚的制备方法。The invention relates to a preparation method of 5-benzyloxy-2-(4-benzyloxyphenyl)-3-methyl-1H-indole.

背景技术Background technique

由Wyeth公司研制的巴多昔芬(bazedoxifene)是新一代SERM(选择性雌激素受体调节剂),它可以竞争性地抑制17β-雌二醇与ERα和ERβ的结合,单独使用对人乳癌细胞系无激动剂活性。临床前试验显示,在同类产品中,它在改善子宫特性方面比雷洛昔芬(第二代SERM)和拉索昔芬(第三代SERM)更具优势,另外,血管舒缩不稳定模型试验显示,它对中枢神经系统副作用很小,在激活肝脂酶启动子方面,它为一种相对有效的激动剂,而雷洛昔芬则无效,当与雷洛昔芬联用时,它能够抑制雷洛昔芬对啮齿类动物子宫的刺激作用,可见二者对子宫的效应是不同的。临床前试验数据表明,它比目前所知的其他SERMs更具靶向活性,是至今“同类产品中之最佳”。该药目前已于2009年在欧盟(商品名:Conbriza)和日本(商品名:Viviant)上市。其首要适应症为治疗和预防绝经期妇女的骨质疏松症。Bazedoxifene, developed by Wyeth, is a new generation of SERM (selective estrogen receptor modulator), which can competitively inhibit the binding of 17β-estradiol to ERα and ERβ, and is used alone for human breast cancer The cell line has no agonist activity. Preclinical tests show that it is superior to raloxifene (second generation SERM) and lasofoxifene (third generation SERM) in improving uterine properties among similar products, and the vasomotor instability model Tests have shown that it has little side effects on the central nervous system, and it is a relatively effective agonist in activating the hepatic lipase promoter, while raloxifene is ineffective. When combined with raloxifene, it can Inhibiting the stimulating effect of raloxifene on the uterus of rodents, it can be seen that the effects of the two on the uterus are different. Preclinical test data show that it has more targeted activity than other SERMs known so far, and it is the "best of its kind" so far. The drug has been launched in the European Union (trade name: Conbriza) and Japan (trade name: Viviant) in 2009. Its primary indication is the treatment and prevention of osteoporosis in postmenopausal women.

醋酸巴多昔芬(Bazedoxifeneacetate)化学名为1-{4-[2-(环己亚胺基-1-)乙氧基]苄基}-2-(4-羟基苯基)-3-甲基-1H-吲哚-5-酚醋酸盐,其制备方法如下:The chemical name of bazedoxifene acetate is 1-{4-[2-(cyclohexylimino-1-)ethoxy]benzyl}-2-(4-hydroxyphenyl)-3-methanol Base-1H-indole-5-phenol acetate, its preparation method is as follows:

5-苄氧基-2-(4-苄氧基苯基)-3-甲基-1H-吲哚(I)是合成醋酸巴多昔芬的关键中间体,其合成主要有以下三种方法:5-benzyloxy-2-(4-benzyloxyphenyl)-3-methyl-1H-indole (I) is a key intermediate in the synthesis of bazedoxifene acetate, and its synthesis mainly has the following three methods :

路线一(US5998402):Route 1 (US5998402):

该路线以2-溴-(4-苄氧基苯基)丙酮(II)、对苄氧基苯胺盐酸盐(III)为起始原料,以DMF为溶剂,回流反应,II与III缩合得5-苄氧基-2-(4-苄氧基苯基)-3-甲基-1H-吲哚(I)。在此反应中,对苄氧基苯胺盐酸盐(III)的用量是2-溴-(4-苄氧基苯基)丙酮(II)的3.5倍(摩尔量比),有大量的对苄氧基苯胺盐酸盐(III)剩余,既给后处理带来了麻烦,需要柱层析纯化,又浪费了原料,且收率低(33%),不适合工业化生产。The route uses 2-bromo-(4-benzyloxyphenyl) acetone (II) and p-benzyloxyaniline hydrochloride (III) as starting materials, DMF as solvent, reflux reaction, and condensation of II and III to obtain 5-Benzyloxy-2-(4-benzyloxyphenyl)-3-methyl-1H-indole (I). In this reaction, the consumption of p-benzyloxyaniline hydrochloride (III) is 3.5 times (molar ratio) of 2-bromo-(4-benzyloxyphenyl) acetone (II), there is a large amount of p-benzyloxyaniline Oxyaniline hydrochloride (III) remains, which not only brings trouble to post-processing, requires column chromatography purification, but also wastes raw materials, and the yield is low (33%), which is not suitable for industrial production.

路线二(US5998402):Route 2 (US5998402):

该路线以路线一为基础,同样以2-溴-(4-苄氧基苯基)丙酮(II)、对苄氧基苯胺盐酸盐(III)为起始原料,以DMF为溶剂,II与III缩合得5-苄氧基-2-(4-苄氧基苯基)-3-甲基-1H-吲哚(I)。不同的是,该路线中两步反应合并为“一锅”反应:第一步中加入三乙胺作碱,II与1.3倍摩尔量的III缩合得中间产物1-(4-苄氧基苯基)-2-[(4-苄氧基苯基)氨基]丙酮(IV),IV不经分离,与再次加入的1.5倍摩尔量的III发生Bischler-Mohlau吲哚关环反应生成产物I。该路线虽然将两步反应合并为“一锅”,简化了反应操作,但为了除去过量的III和杂质,后处理步骤繁琐,所得固体粗品需在甲醇/乙醚中多次打浆洗涤才能得到较纯的产物I,收率较低(55%)。This route is based on route 1, also using 2-bromo-(4-benzyloxyphenyl) acetone (II) and p-benzyloxyaniline hydrochloride (III) as starting materials, using DMF as solvent, II Condensation with III gives 5-benzyloxy-2-(4-benzyloxyphenyl)-3-methyl-1H-indole (I). The difference is that the two-step reactions in this route are combined into a "one-pot" reaction: in the first step, triethylamine is added as a base, and II is condensed with 1.3 times the molar amount of III to obtain the intermediate product 1-(4-benzyloxybenzene Base)-2-[(4-benzyloxyphenyl)amino]acetone (IV), IV was not separated, and the Bischler-Mohlau indole ring closure reaction with 1.5 times molar amount of III was added again to generate product I. Although this route combines the two-step reactions into "one pot", which simplifies the reaction operation, in order to remove excess III and impurities, the post-treatment steps are cumbersome, and the obtained solid crude product needs to be beaten and washed in methanol/ether several times to obtain a relatively pure product. The product I, the yield is lower (55%).

路线三(WO2008098527):Route 3 (WO2008098527):

该路线以2-溴-(4-苄氧基苯基)丙酮(II)、对苄氧基苯胺盐酸盐(III)为起始原料(对苄氧基苯胺盐酸盐(III)的用量是2-溴-(4-苄氧基苯基)丙酮(II)的1.1-1.2倍),以醇(乙醇、异丙醇等)作溶剂,缩合得中间体1-(4-苄氧基苯基)-2-[(4-苄氧基苯基)氨基]丙酮(IV),将IV分离纯化后,IV再与0.2倍摩尔量的III发生Bischler-Mohlau吲哚关环反应得产物I。该路线收率较高(两步总收率60%-75%),但中间产物IV需分离纯化,增加了反应操作,整条路线不够简洁。This route takes 2-bromo-(4-benzyloxyphenyl) acetone (II) and p-benzyloxyaniline hydrochloride (III) as starting materials (the amount of p-benzyloxyaniline hydrochloride (III) 1.1-1.2 times that of 2-bromo-(4-benzyloxyphenyl) acetone (II), use alcohol (ethanol, isopropanol, etc.) as solvent, and condense to obtain the intermediate 1-(4-benzyloxy Phenyl)-2-[(4-benzyloxyphenyl)amino]acetone (IV), after separating and purifying IV, Bischler-Mohlau indole ring-closing reaction occurs between IV and 0.2 times molar amount of III to obtain product I . The yield of this route is relatively high (the total yield of two steps is 60%-75%), but the intermediate product IV needs to be separated and purified, which increases the reaction operation, and the whole route is not concise enough.

发明内容Contents of the invention

本发明所解决的技术问题在于为了克服现有的5-苄氧基-2-(4-苄氧基苯基)-3-甲基-1H-吲哚的制备工艺复杂、操作繁琐、产率低等缺陷,提供了一种5-苄氧基-2-(4-苄氧基苯基)-3-甲基-1H-吲哚的制备方法。该制备方法操作简单,成本低,大大简化了反应后处理过程,且纯度高,反应收率高,适于放大生产。The technical problem solved by the present invention is in order to overcome the complex preparation process of the existing 5-benzyloxy-2-(4-benzyloxyphenyl)-3-methyl-1H-indole, complicated operation and low yield With low defects, a preparation method of 5-benzyloxy-2-(4-benzyloxyphenyl)-3-methyl-1H-indole is provided. The preparation method is simple in operation, low in cost, greatly simplifies the post-reaction treatment process, has high purity and high reaction yield, and is suitable for scale-up production.

本发明是通过以下技术方案解决上述技术问题的:The present invention solves the above technical problems through the following technical solutions:

本发明提供了5-苄氧基-2-(4-苄氧基苯基)-3-甲基-1H-吲哚的制备方法,其包括下列步骤:The invention provides a preparation method of 5-benzyloxy-2-(4-benzyloxyphenyl)-3-methyl-1H-indole, which comprises the following steps:

(1)在醇类溶剂中,在碱的作用下,将化合物II与化合物III进行缩合反应;(1) In an alcoholic solvent, under the action of a base, conduct a condensation reaction between compound II and compound III;

(2)将步骤(1)的反应液与质子酸混合,进行Bischler-Mohlau吲哚关环反应,即可;(2) Mix the reaction liquid of step (1) with protonic acid, and carry out the Bischler-Mohlau indole ring-closing reaction;

步骤(1)中,所述的醇类溶剂较佳地为正丁醇、异丁醇、正丙醇、异丙醇和乙醇中的一种或多种;更佳地为正丁醇、异丁醇和正丙醇中的一种或多种。所述的醇类溶剂与化合物II的体积质量比较佳地为5~15ml/g。In step (1), the alcohol solvent is preferably one or more of n-butanol, isobutanol, n-propanol, isopropanol and ethanol; more preferably n-butanol, isobutanol One or more of alcohol and n-propanol. The volume mass of the alcohol solvent and compound II is preferably 5-15ml/g.

步骤(1)中,所述的碱较佳地为无机碱和/或有机碱。所述的无机碱较佳地为碳酸钾、碳酸钠、碳酸氢钠、碳酸氢钾、氢氧化钠和氢氧化钾中的一种或多种;所述的有机碱较佳地为三乙胺、吡啶、4-二甲基氨基吡啶、吗啉和N,N-二异丙基乙胺中的一种或多种。所述的碱更佳地为三乙胺。所述的碱与化合物II的摩尔比较佳地为(2:1)~(2.5:1)。In step (1), the base is preferably an inorganic base and/or an organic base. Described inorganic base is preferably one or more in potassium carbonate, sodium carbonate, sodium bicarbonate, potassium bicarbonate, sodium hydroxide and potassium hydroxide; Described organic base is preferably triethylamine One or more of , pyridine, 4-dimethylaminopyridine, morpholine and N,N-diisopropylethylamine. The base is more preferably triethylamine. The molar ratio of the base to compound II is preferably (2:1)-(2.5:1).

步骤(1)中,所述的化合物II与化合物III的摩尔比较佳地为(1:1)~(1:1.2)。In step (1), the molar ratio of compound II to compound III is preferably (1:1)-(1:1.2).

步骤(1)中,所述的缩合反应的温度较佳地为75~160℃,更佳地为100~130℃。所述的缩合反应的进程可通过本领域常规手段(如TLC或HPLC)进行监测,一般以化合物II消失时作为反应的终点,所述的缩合反应的时间较佳地为2~4小时。In step (1), the temperature of the condensation reaction is preferably 75-160°C, more preferably 100-130°C. The progress of the condensation reaction can be monitored by conventional means in the art (such as TLC or HPLC). Generally, the end point of the reaction is when the compound II disappears. The condensation reaction time is preferably 2-4 hours.

本发明中,所述的步骤(1)得到的反应液可不经后处理直接进行步骤(2)。In the present invention, the reaction solution obtained in step (1) can be directly carried out in step (2) without post-treatment.

步骤(2)中,在将步骤(1)的反应液与质子酸混合之前较佳地进行冷却。所述的冷却较佳地为自然冷却至所述的步骤(1)的反应液的温度为10~30℃。In step (2), cooling is preferably performed before mixing the reaction solution in step (1) with the protonic acid. The cooling is preferably natural cooling until the temperature of the reaction liquid in the step (1) is 10-30°C.

步骤(2)中,所述的质子酸较佳地为无机酸和/或有机酸。所述的无机酸较佳地为盐酸、硫酸和磷酸中的一种或多种,更佳地为盐酸;所述的有机酸较佳地为甲酸、乙酸、丙酸、草酸、富马酸、马来酸、琥珀酸、酒石酸、柠檬酸、丙二酸、甲磺酸、苯磺酸、对甲苯磺酸和对甲苯磺酸一水合物中的一种或多种,更佳地为对甲苯磺酸。所述的质子酸与化合物II的摩尔比较佳地为(0.05:1)~(0.3:1)。In step (2), the protic acid is preferably an inorganic acid and/or an organic acid. Described inorganic acid is preferably one or more in hydrochloric acid, sulfuric acid and phosphoric acid, is more preferably hydrochloric acid; Described organic acid is preferably formic acid, acetic acid, propionic acid, oxalic acid, fumaric acid, One or more of maleic acid, succinic acid, tartaric acid, citric acid, malonic acid, methanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid and p-toluenesulfonic acid monohydrate, more preferably p-toluene sulfonic acid. The molar ratio of the protonic acid to compound II is preferably (0.05:1)-(0.3:1).

步骤(2)中,所述的Bischler-Mohlau吲哚关环反应的温度较佳地为75~160℃,更佳地为100~130℃。In step (2), the temperature of the Bischler-Mohlau indole ring closure reaction is preferably 75-160°C, more preferably 100-130°C.

所述的Bischler-Mohlau吲哚关环反应的进程可通过本领域常规手段(如TLC或HPLC)进行监测,所述的Bischler-Mohlau吲哚关环反应的时间较佳地为5~15小时。The progress of the Bischler-Mohlau indole ring-closing reaction can be monitored by conventional means in the art (such as TLC or HPLC), and the time of the Bischler-Mohlau indole ring-closing reaction is preferably 5-15 hours.

其中,所述的Bischler-Mohlau吲哚关环反应结束后还可以进行后处理,进一步纯化化合物I。所述的后处理的方式可为本领域常规的后处理方式,优选包括如下步骤:抽滤,干燥,即可。当所述的碱采用无机碱时,抽滤后较佳地进行水洗,再干燥。Wherein, after the completion of the Bischler-Mohlau indole ring-closing reaction, post-treatment can be carried out to further purify compound I. The post-treatment method can be a conventional post-treatment method in the art, preferably including the following steps: suction filtration and drying. When the base is an inorganic base, it is preferably washed with water after suction filtration, and then dried.

在不违背本领域常识的基础上,上述各优选条件,可任意组合,即得本发明各较佳实例。On the basis of not violating common knowledge in the field, the above-mentioned preferred conditions can be combined arbitrarily to obtain preferred examples of the present invention.

本发明所用试剂和原料均市售可得。The reagents and raw materials used in the present invention are all commercially available.

本发明的积极进步效果在于:本发明的合成路线与原有技术相比较,将第一步缩合反应与第二步Bischler-Mohlau吲哚关环反应合并为“一锅”反应,操作简便;反应液中加入酸,无需再次加入原料化合物III,简化了操作,节省了成本;反应产物I直接从反应溶剂中析出,大大简化了反应后处理过程,且纯度高,反应收率高,适于放大生产。The positive progress effect of the present invention is: the synthetic route of the present invention compares with prior art, and the first step condensation reaction and the second step Bischler-Mohlau indole ring-closing reaction are merged into "one pot" reaction, easy and simple to operate; Reaction Adding acid into the solution does not need to add the raw material compound III again, which simplifies the operation and saves the cost; the reaction product I is directly precipitated from the reaction solvent, which greatly simplifies the post-reaction treatment process, and has high purity and high reaction yield, which is suitable for scale-up Production.

具体实施方式detailed description

下面通过实施例的方式进一步说明本发明,但并不因此将本发明限制在所述的实施例范围之中。下列实施例中未注明具体条件的实验方法,按照常规方法和条件,或按照商品说明书选择。The present invention is further illustrated below by means of examples, but the present invention is not limited to the scope of the examples. For the experimental methods that do not specify specific conditions in the following examples, select according to conventional methods and conditions, or according to the product instructions.

实施例1Example 1

合成5-苄氧基-2-(4-苄氧基苯基)-3-甲基-1H-吲哚(I)Synthesis of 5-benzyloxy-2-(4-benzyloxyphenyl)-3-methyl-1H-indole (I)

2-溴-(4-苄氧基苯基)丙酮(12.7g,0.04mol)、对苄氧基苯胺盐酸盐(11.1g,0.047mol)加至正丁醇(120ml)中,加入三乙胺(12.2ml),升温至118℃回流,3小时后,2-溴-(4-苄氧基苯基)丙酮反应完全;加入浓盐酸(1.0ml),升温至118℃继续反应7小时。反应液冷却,抽滤,干燥得白色固体15.2g,HPLC纯度:98%,收率90.5%。Add 2-bromo-(4-benzyloxyphenyl) acetone (12.7g, 0.04mol), p-benzyloxyaniline hydrochloride (11.1g, 0.047mol) to n-butanol (120ml), add triethyl Amine (12.2ml) was heated to 118°C and refluxed. After 3 hours, the reaction of 2-bromo-(4-benzyloxyphenyl)acetone was complete; concentrated hydrochloric acid (1.0ml) was added, and the temperature was raised to 118°C to continue the reaction for 7 hours. The reaction liquid was cooled, filtered with suction, and dried to obtain 15.2 g of white solid, HPLC purity: 98%, yield 90.5%.

1H-NMR(400MHz,d6-DMSO)δ(ppm):7.798(brs,1H,-NH-),7.102-7.557(m,14H,Ar-H),7.255(d,1H,J=2.4Hz,Ar-H),7.174(d,1H,J=4.0Hz,Ar-H),6.978(dd,1H,J=4.0Hz,2.4Hz,Ar-H),5.192(s,2H,-OCH2-),5.153(s,2H,-OCH2-),2.436(s,3H,-CH3)MS(m/z):420(M+1) 1 H-NMR(400MHz,d 6 -DMSO)δ(ppm):7.798(brs,1H,-NH-),7.102-7.557(m,14H,Ar-H),7.255(d,1H,J=2.4 Hz,Ar-H),7.174(d,1H,J=4.0Hz,Ar-H),6.978(dd,1H,J=4.0Hz,2.4Hz,Ar-H),5.192(s,2H,-OCH 2 -),5.153(s,2H,-OCH 2 -),2.436(s,3H,-CH 3 )MS(m/z):420(M+1)

实施例2Example 2

合成5-苄氧基-2-(4-苄氧基苯基)-3-甲基-1H-吲哚(I)Synthesis of 5-benzyloxy-2-(4-benzyloxyphenyl)-3-methyl-1H-indole (I)

2-溴-(4-苄氧基苯基)丙酮(12.7g,0.04mol)、对苄氧基苯胺盐酸盐(11.1g,0.047mol)加至异丁醇(120ml)中,加入三乙胺(12.2ml),升温至107℃回流,3小时后,2-溴-(4-苄氧基苯基)丙酮反应完全;加入对甲苯磺酸一水合物(1.7g),升温至107℃继续反应14小时。反应液冷却,抽滤,干燥得棕褐色固体14.4g,HPLC纯度:97%,收率86%。Add 2-bromo-(4-benzyloxyphenyl) acetone (12.7g, 0.04mol), p-benzyloxyaniline hydrochloride (11.1g, 0.047mol) to isobutanol (120ml), add triethyl Amine (12.2ml), heated to 107°C and refluxed, 2-bromo-(4-benzyloxyphenyl)acetone reacted completely after 3 hours; added p-toluenesulfonic acid monohydrate (1.7g), heated to 107°C The reaction was continued for 14 hours. The reaction solution was cooled, filtered with suction, and dried to obtain 14.4 g of a tan solid, with an HPLC purity of 97% and a yield of 86%.

实施例3Example 3

合成5-苄氧基-2-(4-苄氧基苯基)-3-甲基-1H-吲哚(I)Synthesis of 5-benzyloxy-2-(4-benzyloxyphenyl)-3-methyl-1H-indole (I)

2-溴-(4-苄氧基苯基)丙酮(12.7g,0.04mol)、对苄氧基苯胺盐酸盐(11.1g,0.047mol)加至异丙醇(120ml)中,加入吡啶(7.1ml),升温至84℃,4小时后,2-溴-(4-苄氧基苯基)丙酮反应完全;加入乙酸(0.7ml)继续反应15小时。反应液冷却,抽滤,干燥得白色固体14.6g,HPLC纯度:96%,收率87%。Add 2-bromo-(4-benzyloxyphenyl) acetone (12.7g, 0.04mol), p-benzyloxyaniline hydrochloride (11.1g, 0.047mol) to isopropanol (120ml), add pyridine ( 7.1ml), the temperature was raised to 84°C, and after 4 hours, the reaction of 2-bromo-(4-benzyloxyphenyl)acetone was complete; acetic acid (0.7ml) was added to continue the reaction for 15 hours. The reaction solution was cooled, filtered with suction, and dried to obtain 14.6 g of white solid, HPLC purity: 96%, yield 87%.

实施例4Example 4

合成5-苄氧基-2-(4-苄氧基苯基)-3-甲基-1H-吲哚(I)Synthesis of 5-benzyloxy-2-(4-benzyloxyphenyl)-3-methyl-1H-indole (I)

2-溴-(4-苄氧基苯基)丙酮(12.7g,0.04mol)、对苄氧基苯胺盐酸盐(11.1g,0.047mol)加至正丁醇(120ml)中,加入吗啉(7.7ml),升温至118℃,3小时后,2-溴-(4-苄氧基苯基)丙酮反应完全;加入浓硫酸(0.6ml),继续反应7小时。反应液冷却,抽滤,干燥得白色固体14.7g,HPLC纯度:98%,收率88%。Add 2-bromo-(4-benzyloxyphenyl)acetone (12.7g, 0.04mol), p-benzyloxyaniline hydrochloride (11.1g, 0.047mol) to n-butanol (120ml), add morpholine (7.7ml), the temperature was raised to 118°C, and after 3 hours, the reaction of 2-bromo-(4-benzyloxyphenyl)acetone was complete; concentrated sulfuric acid (0.6ml) was added, and the reaction was continued for 7 hours. The reaction solution was cooled, filtered with suction, and dried to obtain 14.7 g of white solid, HPLC purity: 98%, yield 88%.

实施例5Example 5

合成5-苄氧基-2-(4-苄氧基苯基)-3-甲基-1H-吲哚(I)Synthesis of 5-benzyloxy-2-(4-benzyloxyphenyl)-3-methyl-1H-indole (I)

2-溴-(4-苄氧基苯基)丙酮(12.7g,0.04mol)、对苄氧基苯胺盐酸盐(11.1g,0.047mol)加至正丁醇(120ml)中,加入碳酸钠(9.3g),升温至118℃回流,3小时后,2-溴-(4-苄氧基苯基)丙酮反应完全;加入浓盐酸(1.0ml),升温至118℃继续反应7小时。反应液冷却,抽滤,所得固体水洗(60ml),过滤,干燥得白色固体14.8g,HPLC纯度:99%,收率88%。Add 2-bromo-(4-benzyloxyphenyl)acetone (12.7g, 0.04mol), p-benzyloxyaniline hydrochloride (11.1g, 0.047mol) to n-butanol (120ml), add sodium carbonate (9.3g), heated to 118°C and refluxed. After 3 hours, the reaction of 2-bromo-(4-benzyloxyphenyl)acetone was complete; concentrated hydrochloric acid (1.0ml) was added, and the temperature was raised to 118°C to continue the reaction for 7 hours. The reaction solution was cooled, filtered with suction, the obtained solid was washed with water (60ml), filtered, and dried to obtain 14.8g of white solid, HPLC purity: 99%, yield 88%.

Claims (10)

  1. The preparation method of 1.5-benzyloxy-2-(4-benzyloxy phenyl)-3-Methyl-1H-indole, is characterized in that,It comprises the following steps:
    (1), in alcohols solvent, under the effect of alkali, Compound I I and compound III are carried out to condensationReaction;
    (2) reactant liquor of step (1) is mixed with Bronsted acid, carry out Bischler-Mohlau indoles passRing reaction;
  2. 2. preparation method as claimed in claim 1, is characterized in that, in step (1), describedAlcohols solvent is one or more in n-butanol, isobutanol, normal propyl alcohol, isopropyl alcohol and ethanol; DescribedAlcohols solvent be 5~15ml/g with the volume mass ratio of Compound I I.
  3. 3. preparation method as claimed in claim 1, is characterized in that, in step (1), describedAlkali is inorganic base and/or organic base, and described inorganic base is potash, sodium carbonate, sodium acid carbonate, carbonic acidOne or more in hydrogen potassium, NaOH and potassium hydroxide, described organic base be triethylamine, pyridine,One or more in 4-dimethylaminopyridine, morpholine and DIPEA.
  4. 4. preparation method as claimed in claim 1, is characterized in that, described alkali and Compound I IMol ratio be (2:1)~(2.5:1).
  5. 5. preparation method as claimed in claim 1, is characterized in that, in step (1), describedThe mol ratio of Compound I I and compound III is (1:1)~(1:1.2).
  6. 6. preparation method as claimed in claim 1, is characterized in that, in step (1), describedThe temperature of condensation reaction is 75~160 DEG C; In step (2), described Bischler-Mohlau indoles closesThe temperature of ring reaction is 75~160 DEG C.
  7. 7. preparation method as claimed in claim 6, is characterized in that, in step (1), describedThe temperature of condensation reaction is 100~130 DEG C; In step (2), described Bischler-Mohlau indolesThe temperature of ring closure reaction is 100~130 DEG C.
  8. 8. preparation method as claimed in claim 1, is characterized in that, in step (2), will walkSuddenly the reactant liquor of (1) carries out before mixing with Bronsted acid coolingly, and described being cooled to naturally cools to instituteThe temperature of the reactant liquor of the step (1) of stating is 10~30 DEG C.
  9. 9. preparation method as claimed in claim 1, is characterized in that, in step (2), describedBronsted acid is inorganic acid and/or organic acid; Described inorganic acid be a kind of in hydrochloric acid, sulfuric acid and phosphoric acid orMultiple; Described organic acid be formic acid, acetic acid, propionic acid, oxalic acid, fumaric acid, maleic acid, butanedioic acid,Tartaric acid, citric acid, malonic acid, methanesulfonic acid, benzene sulfonic acid, p-methyl benzenesulfonic acid and p-methyl benzenesulfonic acid one waterOne or more in compound.
  10. 10. preparation method as claimed in claim 1, is characterized in that, described Bronsted acid and chemical combinationThe mol ratio of thing II is (0.05:1)~(0.3:1).
CN201310120074.4A 2013-04-08 2013-04-08 The preparation method of 5-benzyloxy-2-(4-benzyloxy phenyl)-3-Methyl-1H-indole Active CN104098499B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201310120074.4A CN104098499B (en) 2013-04-08 2013-04-08 The preparation method of 5-benzyloxy-2-(4-benzyloxy phenyl)-3-Methyl-1H-indole

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201310120074.4A CN104098499B (en) 2013-04-08 2013-04-08 The preparation method of 5-benzyloxy-2-(4-benzyloxy phenyl)-3-Methyl-1H-indole

Publications (2)

Publication Number Publication Date
CN104098499A CN104098499A (en) 2014-10-15
CN104098499B true CN104098499B (en) 2016-05-04

Family

ID=51667085

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201310120074.4A Active CN104098499B (en) 2013-04-08 2013-04-08 The preparation method of 5-benzyloxy-2-(4-benzyloxy phenyl)-3-Methyl-1H-indole

Country Status (1)

Country Link
CN (1) CN104098499B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT201800006562A1 (en) * 2018-06-21 2019-12-21 PROCEDURE AND USEFUL INTERMEDIATES FOR THE PREPARATION OF INDOLES

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5880137A (en) * 1996-04-19 1999-03-09 American Home Products Corporation 2-phenyl-1- 4-(amino-1-yl-alk-1-ynyl)-benzyl!-1H-indol-5-ols as estrogenic agents
CN1309637A (en) * 1998-05-15 2001-08-22 美国家用产品公司 Compositions comprising 2-phenyl-indole compounds and estrogen formutations
WO2004099139A1 (en) * 2000-09-15 2004-11-18 Baylor University Indole-containing compounds with anti-tubulin and vascular targeting activity
WO2008098527A1 (en) * 2007-02-12 2008-08-21 Zentiva A.S. Method for the preparation of 5-benzyloxy-2-(4-benzyloxphenyl)-3-methyl-1h-indole

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4187441B2 (en) * 1999-09-17 2008-11-26 ベイラー・ユニバーシテイ Indole-containing and combretastatin-related antimitotic and antitubulin polymerization drugs

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5880137A (en) * 1996-04-19 1999-03-09 American Home Products Corporation 2-phenyl-1- 4-(amino-1-yl-alk-1-ynyl)-benzyl!-1H-indol-5-ols as estrogenic agents
CN1309637A (en) * 1998-05-15 2001-08-22 美国家用产品公司 Compositions comprising 2-phenyl-indole compounds and estrogen formutations
WO2004099139A1 (en) * 2000-09-15 2004-11-18 Baylor University Indole-containing compounds with anti-tubulin and vascular targeting activity
WO2008098527A1 (en) * 2007-02-12 2008-08-21 Zentiva A.S. Method for the preparation of 5-benzyloxy-2-(4-benzyloxphenyl)-3-methyl-1h-indole

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
cient one-pot synthesis of indoles.《Tetrahedron Letters》.2007,第49卷全文. *
Design, Synthesis, and Preclinical Characterization of Novel, Highly Selective Indole Estrogens;Chris P.Miller等;《J.Med.Chem.》;20010425;第44卷(第11期);第1654-1657页 *
George Bratulescu.A new and e&#64259 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT201800006562A1 (en) * 2018-06-21 2019-12-21 PROCEDURE AND USEFUL INTERMEDIATES FOR THE PREPARATION OF INDOLES

Also Published As

Publication number Publication date
CN104098499A (en) 2014-10-15

Similar Documents

Publication Publication Date Title
KR101808792B1 (en) Process for large scale production of 1-[(2-bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1h-indole dimesylate monohydrate
JP2013504563A (en) Process for the preparation of indoline derivatives and intermediates thereof
CN103339116B (en) Replace n-valeramide compounds, Preparation Method And The Use
JP2013531054A (en) Method for preparing aminobenzoylbenzofuran derivatives
JP7339946B2 (en) Method for producing 2-(5-methoxyisochroman-1-yl)-4,5-dihydro-1H-imidazole and hydrogen sulfate thereof
CN102120739A (en) Preparation method of fasudil hydrochloride
CN105693603B (en) The maleic acid datro preparation process of improvement
CN107698538B (en) Preparation method of intermediate 3- (1-piperidinylmethyl) phenol of roxatidine acetate hydrochloride
CN112062767A (en) Preparation method and intermediate of rumepilone
CN104098499B (en) The preparation method of 5-benzyloxy-2-(4-benzyloxy phenyl)-3-Methyl-1H-indole
CA2756234C (en) Synthesis of 3-{[(2r)-1-methylpyrrolidin-2-yl]methyl}-5-[2-(phenylsulfonyl)ethyl]-1h-indole
CN101481333B (en) Novel rivastigmine preparation
CN107935866B (en) Preparation method of dapoxetine hydrochloride impurity
ES2431359T3 (en) New procedure for the preparation of Eletriptan
CN101481335B (en) Rivastigmine intermediate preparation
US20160304452A1 (en) Method for preparing silodosin and intermediate thereof
JP2015038053A (en) Method for producing 4-(2-methyl-1-imidazolyl)-2,2-phenylbutane amide
ES2436027T3 (en) Procedure for the preparation of almotriptane
WO2008072257A2 (en) Process for the preparation of indole derivatives
CN111499528A (en) Terbutaline sulfate intermediate, preparation method thereof and method for preparing terbutaline sulfate by using terbutaline sulfate intermediate
CN106554254A (en) A kind of synthetic method of 2,3 ', 4,5 ' tetrahydroxy bibenzyl of natural product
CN101514167A (en) Method for preparing chiral baclofen
JP2016511761A (en) Method for synthesizing 4-piperidin-4-yl-benzene-1,3-diol and salts thereof, and novel compound tert-butyl 4- (2,4-dihydroxy-phenyl) -4-hydroxy-piperidine-1-carboxylate
CN100432052C (en) Synthetic method for methoxy indole
WO2013001511A1 (en) Novel salt intermediates for the synthesis of bazedoxifene acetate and process thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
C41 Transfer of patent application or patent right or utility model
CB03 Change of inventor or designer information

Inventor after: Chen Pan

Inventor after: Yuan Zhedong

Inventor after: Liu Xiangkui

Inventor after: Kong Rui

Inventor after: Gu Hongmei

Inventor after: Wang Xiangjian

Inventor before: Chen Pan

Inventor before: Yuan Zhedong

Inventor before: Liu Xiangkui

Inventor before: Kong Rui

COR Change of bibliographic data
GR01 Patent grant
TA01 Transfer of patent application right

Effective date of registration: 20160413

Address after: 200040 Beijing West Road, Shanghai, No. 1320, No.

Applicant after: Shanghai Institute of pharmaceutical industry

Applicant after: China State Institute of Pharmaceutical Industry

Applicant after: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Address before: 200040 Beijing West Road, Shanghai, No. 1320, No.

Applicant before: Shanghai Institute of pharmaceutical industry

Applicant before: China State Institute of Pharmaceutical Industry